Document is current
Any future updates will be listed below
-
Authors
Qin, Ruzhai
Ye, Lika
Duan, Lian
Li, Mingyan
He, Wenkai
Mei, Xiao
Li, Deen
Jin, Rong
Lv, Chao
Zhu, Min
Wang, Shihui
Xie, Zhihong
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05432544 at ClinicalTrials.govDocuments that mention this clinical trial
SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study
https://doi.org/10.1007/s40262-025-01539-8
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Medicine
- License Information
-
More Information
Article History
Accepted: 2 June 2025
First Online: 27 June 2025
Declarations
:
: This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
: Chao Lv, Min Zhu, and Shihui Wang are employees of Hengrui. Ruzhai Qin, Lika Ye, Lian Duan, Mingyan Li, Wenkai He, Xiao Mei, Deen Li, Rong Jin, and Zhihong Xie have no conflicts of interest that are directly relevant to the content of this article.
: The protocol and all amendments were approved by the Clinical Trial Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University. The study was conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.
: Not applicable.
